智通财经APP讯，亚辉龙(688575.SH)发布关于自愿披露签署战略合作框架协议的补充公告，公告称： 深圳脑机星链科技有限公司(简称："脑机星链")成立时间短，规模较小，目前在睡眠产品方向主要开发 产品有脑电采集分析仪、脑机接口助眠仪、脑机接口睡眠监测仪、迷走神经刺激仪，相关产品尚未进入 注册申报阶段，其中，迷走神经刺激仪处于二类医疗器械证书注册检准备阶段;在阿尔茨海默症、孤独 症、脑卒中诊断领域相关产品目前尚处于早期研发阶段或临床前阶段。脑机星链目前在研产品的技术路 线为非侵入式技术路径，与马斯克创建的脑机接口公司Neuralink在技术路线上存在本质区别，目前也尚 无侵入式技术布局。 ...

北京商报讯（记者 丁宁）1月6日晚间，亚辉龙（688575）发布签署战略合作框架协议的补充公告称， 深圳脑机星链科技有限公司（以下简称"脑机星链"）成立时间短，规模较小，目前在睡眠产品方向主要 开发产品有脑电采集分析仪、脑机接口助眠仪、脑机接口睡眠监测仪、迷走神经刺激仪，相关产品尚未 进入注册申报阶段，其中，迷走神经刺激仪处于二类医疗器械证书注册检准备阶段；在阿尔茨海默症、 孤独症、脑卒中诊断领域相关产品目前尚处于早期研发阶段或临床前阶段。 此外，亚辉龙表示，脑机星链目前在研产品的技术路线为非侵入式技术路径，与马斯克创建的脑机接口 公司 Neuralink 在技术路线上存在本质区别，目前也尚无侵入式技术布局。 据了解，1月6日晚间，亚辉龙公告称，公司于近日与脑机星链签署了《战略合作框架协议》，双方共同 达成战略合作，通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研产品及推进后续 市场拓展及推广，提升在中枢神经疾病等领域诊疗技术水平。随后，针对这一事项，上交所向亚辉龙下 发问询函。 ...

Core Insights - Qiang Brain Technology has completed approximately 2 billion yuan in financing, marking the second-largest funding round in the global brain-computer interface (BCI) sector, following Neuralink [1] - The investment round included prominent firms such as IDG Capital and Huaden International, as well as strategic investments from companies like Weir Shares and Runze Technology [1] - Qiang Brain Technology is recognized as one of the leading companies in the BCI field, having received FDA and CE certifications for its products and being one of the largest investors in BCI research and development globally [1] Company Overview - Founded in February 2015, Qiang Brain Technology originated from Harvard University's innovation lab and focuses on non-invasive BCI technology [1] - The company has launched several products, including smart bionic limbs and brain-machine intelligent sleep devices [1] - Qiang Brain Technology has undergone multiple funding rounds since 2016 and is considering an IPO in the Hong Kong or A-share market [1] Industry Perspective - Neuralink remains the leading company in the BCI sector with a valuation of 9 billion USD and plans to initiate large-scale production of BCI devices by 2026 [2] - The BCI technology is expected to transition from medical necessity to AI applications, indicating a potential commercialization phase starting in 2026 [2] - The A-share market has seen significant interest in BCI-related stocks, with companies like Innovation Medical and Aipeng Medical experiencing consecutive trading limit increases [2] Market Trends - The BCI market is currently in its early commercialization stage, with a focus on thematic investments [2] - There is a distinction between invasive and non-invasive technology paths, with some invasive products already approved for market release, while non-invasive technologies have a clearer commercialization path [2] - Scarcity in hardware and materials related to electrodes, chips, and membranes presents investment opportunities in the BCI sector [2]

每经AI快讯，1月6日，亚辉龙(688575.SH)发布自愿披露签署战略合作框架协议的补充公告称，脑机星 链成立时间短，规模较小，目前在睡眠产品方向主要开发产品有脑电采集分析仪、脑机接口助眠仪、脑 机接口睡眠监测仪、迷走神经刺激仪，相关产品尚未进入注册申报阶段，其中，迷走神经刺激仪处于二 类医疗器械证书注册检准备阶段；在阿尔茨海默症、孤独症、脑卒中诊断领域相关产品目前尚处于早期 研发阶段或临床前阶段。脑机星链目前在研产品的技术路线为非侵入式技术路径，与马斯克创建的脑机 接口公司Neuralink在技术路线上存在本质区别，目前也尚无侵入式技术布局。 ...

Group 1 - Lei Jun, the founder of Xiaomi, addressed the controversy surrounding "small font marketing," stating it is an industry habit that needs to be changed, emphasizing the importance of legal compliance while acknowledging the need for clearer communication with consumers [3][4] - Xiaomi plans to standardize product annotations using larger fonts in the future, aiming to improve clarity and consumer understanding [4] - In a recent live stream, Lei Jun revealed that Xiaomi's automotive division aims to deliver over 410,000 vehicles by 2025, with the Xiaomi YU7 model becoming the best-selling mid-to-large SUV for four consecutive months [5][7] Group 2 - BMW China announced a systematic price adjustment for 31 key models starting January 1, 2026, with the highest price drop reaching 300,000 yuan, reflecting a long-term strategy rather than a short-term price war [11][12] - The flagship electric model i7 M70L saw a price reduction from 1.899 million yuan to 1.598 million yuan, a decrease of approximately 16%, while the iX1 eDrive25L's price dropped by 24% [12] - The automotive industry is experiencing significant shifts, with multiple companies reporting their sales figures for 2025, indicating a competitive landscape [7] Group 3 - OpenAI is reportedly working on multiple AI hardware projects, including a pen-shaped device and portable audio equipment, aiming to create an ecosystem of products rather than a single offering [9][10] - The new audio model being developed by OpenAI is expected to provide more natural and expressive responses, enhancing user interaction with AI devices [10] Group 4 - Elon Musk announced that Neuralink plans to begin large-scale production of brain-machine interface devices in 2026, with a focus on simplifying the surgical process for implantation [16][18] - The company aims to enable users to control computers directly through neural signals, with previous successful trials involving a limited number of patients [18] Group 5 - Microsoft CEO Satya Nadella emphasized that 2026 will be a pivotal year for AI, marking a transition from initial exploration to widespread application, with a focus on reshaping human-AI relationships and engineering paradigms [27][29][30] - Nadella highlighted the need for AI to demonstrate tangible positive impacts in the real world to gain societal acceptance [30]

1月5日，2026年A股第一个交易日，受到马斯克宣布脑机接口将量产消息的刺激，脑机接口概念板块多 只个股涨停，其中倍益康30cm涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通等十余只个 股20cm涨停，南京熊猫、亿嘉和等个股10cm涨停。 收盘至晚间，多家上市公司开始密集披露脑机接口相关进展，进一步点燃市场热情。 首先是亿嘉和，其在收盘后披露2025年12月份投资者关系活动中的内容，表示公司积极探索包括"脑机 接口"在内的前沿技术与具身智能机器人技术融合，并表示已与麦澜德签署战略合作协议，旨在共同探 索"脑机接口+具身智能机器人"技术在智能康养等场景的应用可能性。 2026年开年，A股市场的首个交易日，脑机接口概念板块成为最亮眼的明星。 1月6日，该板块延续前一日的热度，倍益康、美好医疗、三博脑科、岩山科技、南京熊猫、创新医疗等 多股竞价涨停，伟思医疗、爱朋医疗、熵基科技、翔宇医疗等高开超10%。 这场资本狂欢的导火索，来自特斯拉创始人埃隆·马斯克在2025年12月31日发布的重磅消息。当天马斯 克在社交媒体上宣布，其脑机接口公司Neuralink将于2026年"大规模生产"其脑机接口产品。而十几天 前 ...

Core Insights - The brain-computer interface (BCI) industry is transitioning from "scientific experiments" to "commercialization," with Neuralink planning large-scale production by 2026, igniting market expectations [1] - China is accelerating its progress in the BCI field through supportive policies and technological breakthroughs, with significant investments being made in the sector [1][12] - The market is characterized as a "0 to 1" incremental market, driven by short-term sentiment from Neuralink's production expectations and favorable domestic policies [1] Investment Landscape - Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking the second-largest funding round in the BCI sector after Neuralink [1] - Investors are advised to focus on companies with core technological advantages, such as self-developed chips and flexible electrodes, as well as those that can achieve commercial closure in rehabilitation and consumer electronics [1] Technology Comparison - The BCI technology landscape is divided into invasive, semi-invasive, and non-invasive routes, each with distinct differences in signal quality, safety, and commercialization timelines [2] - Invasive methods, like those used by Neuralink, involve surgical implantation of electrodes for high-resolution signal acquisition but come with high costs and long development cycles [5] - Non-invasive methods utilize external sensors for signal collection, offering lower costs and safety but facing challenges with signal attenuation [8] Competitive Landscape - The U.S. leads in invasive BCI technology by 2-5 years, while China is catching up, particularly in non-invasive applications where both countries are on par [9][11] - Chinese companies are making significant strides in clinical trials, with several achieving notable milestones in both invasive and non-invasive technologies [12] Company Developments - Companies like BrainCo and Huashan Hospital have completed pioneering clinical trials in invasive BCI systems, demonstrating the ability to control devices through thought [12][13] - Strong Brain Technology has received FDA and CE certifications, positioning itself as a leader in the commercialization of BCI products [12] - Other companies, such as Beijing Chip Intelligence and ZhiDian Medical, are also advancing in the invasive BCI space, with various clinical trials and product developments underway [13][14] Regulatory Environment - The Chinese government has included BCI in its national strategic emerging industries, with plans for independent billing standards and industry regulations to facilitate commercialization [11]

Core Insights - Neuralink has announced the mass production of "fully automated piercing" surgeries, aiming to significantly reduce costs, bringing science fiction closer to reality [1] - The underlying logic of this development is not just about medical rehabilitation but represents a shift in human-machine "bandwidth," addressing the inefficiencies in human interaction with machines [3][4] Industry Implications - The development of brain-computer interfaces (BCI) could lead to a new concept known as brain-machine IoT, focusing on industrial applications rather than just entertainment or healthcare [4] - Current human-machine interaction in industrial settings is limited, with operators relying on outdated input methods, which creates a mismatch in response times compared to machines [5] - BCI technology could transform human operators into "biological edge nodes" within the IoT framework, allowing for real-time cognitive adaptation in industrial processes [5][6] Technological Advancements - BCI could enable systems to read operators' brain signals, allowing for automatic adjustments in production processes based on the operator's cognitive state, thus enhancing safety and efficiency [6][7] - The introduction of BCI could facilitate a new operational model termed "intent operation," where workers can convey their intentions without needing to control every mechanical detail [11][12] Market Opportunities - BCI technology is seen as a low-cost solution for addressing complex, non-standard tasks in industrial environments, which current AI systems struggle to handle [8] - The potential for data collection from skilled operators using BCI could provide valuable training material for the next generation of humanoid robots [12] Future Directions - The industry may need to shift from invasive physical connections to non-invasive sensing technologies, such as near-infrared spectroscopy and quantum sensors, to capture brain signals without surgical procedures [13][18] - The successful integration of these technologies could lead to a new era of "intent IoT," where human intuition and perception become integral to industrial networks [19]

今日， 被称作"杭州六小龙"之一的强脑科技被曝完成约20亿元融资，为脑机接口领域除马斯克旗下的Neuralink以外世界第二大规模融资。 以下文章来源于科创日报 ，作者张真 科创日报 . 科创圈都在关注的主流媒体，上海报业集团主管主办，《科创板日报》出品。 可孚医疗在互动平台表示，公司非常关注并看好脑机接口赛道，所以在早期以战略投资的方式进行布局。2025年底，公司投资力 之智能，持股比例12.45%。该公司致力于非侵入式脑机接口机器人等产品研发，未来有望与公司康复辅具类、呼吸支持类产品实现 战略协同。 开源证券1月6日研报表示，考虑到脑机接口目前处于商业化起步阶段，当前市场主要以主题投资风格为主，建议关注美股映射机遇和侵入式 脑机临床试验进度。从产业趋势上看，建议侵入式和非侵入式参考不同的标准，部分临床进展较快，神经调控等产品已经获批，非侵入式产 品商业化路径明确，规模化收入潜力可期。此外在软件、硬件（电极、芯片）及实验材料和设备（脑膜、DSA等）方面的脑机接口标的具有 稀缺性。 据悉，此次投资人阵容强大，包括著名投资机构IDG、由英特尔CEO陈立武创 立的华登国际，"果链"巨头蓝思科技、领益智造，战略投资 ...

三博脑科于1月6日晚间发布股票交易异常波动公告。公司在公告中表示，其是以神经专科为特色的医疗 服务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。 该公司在公告中明确澄清，其目前不涉及脑机接口产品的研发、生产及销售业务。同时，公司指出，神 经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：观察君 近期，脑机接口领域动态频发。美国企业家埃隆·马斯克于2025年12月31日通过社交平台发布消息，称 其旗下Neuralink计划于2026年启动脑机接口设备"大规模生产"，并推进几乎完全自动化的手术方案。此 外，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独立实 体，主攻基于超声波的非侵入式脑信号读取技术。 ...